🇺🇸 FDA
Pipeline program

NS2 Ophthalmic Drops (0.5%)

ALDNS2-203-D1

Phase 2 small_molecule completed

Quick answer

NS2 Ophthalmic Drops (0.5%) for Allergic Conjunctivitis is a Phase 2 program (small_molecule) at Aldeyra Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Aldeyra Therapeutics
Indication
Allergic Conjunctivitis
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials